Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, commonly known as Vertex, is a leading biotechnology company headquartered in the United States. Founded in 1989, Vertex has established itself as a pioneer in the development of transformative therapies for serious diseases, particularly in the field of cystic fibrosis. With major operational regions across North America and Europe, the company focuses on innovative drug discovery and development. Vertex is renowned for its unique portfolio of cystic fibrosis treatments, including Kalydeco, Orkambi, and Trikafta, which have significantly improved the quality of life for patients. The company’s commitment to research and development has positioned it as a market leader, achieving notable milestones such as the first approved therapy for the underlying cause of cystic fibrosis. Vertex continues to drive advancements in biotechnology, solidifying its reputation as a key player in the industry.
DitchCarbon Score
How does Vertex Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Vertex Pharmaceuticals's score of 50 is higher than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Vertex Pharmaceuticals's reported carbon emissions
In 2024, Vertex Pharmaceuticals reported total carbon emissions of approximately 551,647,000 kg CO2e, with emissions distributed across various scopes: 8,976,000 kg CO2e for Scope 1, 3,930,000 kg CO2e for Scope 2, and the remaining 551,647,000 kg CO2e attributed to Scope 3. The combined total for Scope 1 and Scope 2 emissions was about 12,906,000 kg CO2e. In 2023, the company recorded total emissions of about 474,129,000 kg CO2e, with Scope 1 emissions at 8,311,000 kg CO2e and Scope 2 emissions at 4,888,000 kg CO2e, leading to a total of approximately 13,198,000 kg CO2e for Scope 1 and 2 combined. Vertex Pharmaceuticals has not set specific reduction targets or initiatives as part of the Science Based Targets initiative (SBTi) or other climate pledges. The company’s emissions data is not cascaded from any parent organisation, indicating that all reported figures are independently sourced from Vertex Pharmaceuticals Incorporated. Overall, Vertex Pharmaceuticals is actively monitoring its carbon footprint across all scopes, but further commitments or reduction strategies have yet to be disclosed.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | - | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | - | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Vertex Pharmaceuticals is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
